Swipe Left For English News 中国上海, 2024年8月6日 全球领先的合同研究、开发和生产CRDMO服务公司药明生物（WuXi Biologics, 2269.HK）宣布，其在标普全球（S&P Global）近日于北京举行的“把握机遇，驱动可持续发展未来——标普全球Sustainable1研讨会暨《可持续发展年鉴（中国版）2024》发布典礼”活动中，入选标普全球《可持续发展年鉴（中国版）2024》，并获颁“全球最佳1%”及“行业最佳进步企业”殊荣。 标普全球《可持续发展年鉴2024》以2023年CSA评分结果为基础，衡量企业可持续发展绩效，识别各行业可持续发展表现优异的企业。今年，共有129家企业从1700余家受评中国企业中脱颖而出，入选标普全球《可持续发展年鉴（中国版）2024》。 今年4月，药明生物凭借在可持续发展领域的卓越表现，入选标普全球《可持续发展年鉴2024》，获评“全球最佳1%”及“行业最佳进步企业”。 陈智胜 博士 药明生物首席执行官 ESG委员会主席 我们很高兴成功入选标普全球《可持续发展年鉴2024（中国版）》，这是继入选2023年标普道琼斯可持续发展世界指数（DJSI World）和道琼斯新兴市场指数（DJSI Emerging Markets Index）后的又一佳绩。这些成就是对我们不断致力于提高环境、社会和公司治理能力，进一步深化公司可持续发展，促进全球社会共同利益的体现和认可。 药明生物在联合国可持续发展目标的指导下，沿着可持续发展道路稳步向前。去年，公司签署科学碳目标倡议（SBTi）承诺书，加入联合国全球契约组织（UNGC），以实际行动履行其对企业和社会可持续发展的承诺。 此外，公司的战略和举措得到了全球评级机构的广泛认可：在明晟MSCI ESG评级中获得AAA评级、获得国际权威企业可持续发展评估机构EcoVadis授予的“铂金”奖牌；2024年，公司入选明晟MSCI ESG 领导者指数、获评晨星Sustainalytics“行业最高评级”和“区域（亚太）最高评级”企业、跻身CDP水安全“A级榜单”并获得CDP气候变化领导力级别评分A-、入选富时社会责任指数系列（FTSE4Good Index Series），充分彰显了公司在可持续发展领域的卓越表现。 推荐阅读 药明生物入选标普全球 《可持续发展年鉴2024》 关于药明生物 药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）服务公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。 药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2023年12月底，药明生物帮助客户研发和生产的综合项目高达698个，其中包括24个商业化生产项目。 药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。 更多信息，请访问：www.wuxibiologics.com ESG esg@wuxibiologics.com 媒体关系 PR@wuxibiologics.com Global Top 1%: WuXi Biologics Included in S&P Global's Sustainability Yearbook 2024 (China Edition) Shanghai, August 6, 2024 WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in S&P Global's Sustainability Yearbook 2024 (China Edition) – with a Global Top 1% S&P Global Corporate Sustainability Assessment (CSA) ranking – and named as an Industry Mover. The recognitions were announced at the recent S&P Global Sustainable1 Sustainability Seminar in Beijing. S&P Global's Sustainability Yearbook is the only analysis of its kind based on its annual CSA evaluation, and it serves as a benchmarking resource for corporate sustainability performance. More than 1,700 companies assessed in the 2023 CSA were considered for inclusion in the Yearbook 2024 (China Edition). S&P Global identified the top performing companies in each industry, and from those selected 129 with the best performance for listing in the Yearbook. Earlier this year, WuXi Biologics was included into the global Sustainability Yearbook, with the Global Top 1% score and the recognition of Industry Mover in its global ranking. Dr. Chris Chen Chief Executive Officer Chairman of the ESG Committee WuXi Biologics We are very pleased to be included in the S&P Global Yearbook, following our inclusion in the DJSI World Index and Emerging Markets Index last year. These achievements are a reflection of and recognition for our continuous commitment to enhancing ESG capabilities and further advancing the company's sustainability performance for the common good of the global community. In line with the United Nations Sustainable Development Goals, WuXi Biologics has been making steady progress in pursuing sustainable development. In the past year, the company signed the Science Based Targets initiative (SBTi) commitment letter and became a signatory to the United Nations Global Compact, demonstrating its sustainability commitment. The company's efforts have been recognized by major ESG rating agencies. It was granted an "AAA" rating from MSCI ESG Ratings; awarded the distinguished Platinum Medal by EcoVadis. Earlier this year, the company was named to MSCI ESG Leaders Indexes; recognized as an Industry and Regional Top-Rated Company by Sustainalytics; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; and named a Constituent of the FTSE4Good Index Series. About WuXi Biologics WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2023, WuXi Biologics is supporting 698 integrated client projects, including 24 in commercial manufacturing. WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com. Contacts ESG esg@wuxibiologics.com Media PR@wuxibiologics.com 注：本信息不构成药明生物的信息披露或投资建议
2026-03-09
35页
购买咨询
400-9696-311 转1
问题咨询
400-9696-311 转2
商务合作
400-9696-311 转3
投诉及建议
400-9696-311 转4
关注摩熵医药公众号
随时查阅行业资讯
摩熵医药数据小程序
掌上数据查询系统
川公网安备51019002008863号
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
收藏
登录后参与评论
暂无评论